Retrospective analysis of cases with HBV reactivation after Hematopoietic Stem Cell Transplantation

Retrospective analysis of cases with HBV reactivation after Hematopoietic Stem Cell Transplantation - HBV reset

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046803

Enrollment

100

Registered

2022-02-03

Start date

2022-02-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HBV reactivation after hematopoietic cell transplantation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) A patient who developed HBV reactivation after HSCT and treated by nucleotide analogue during the period from 2010 Jun to 2020 Dec. 2) any hematological disorder, any number of times of HCT, any stem cell donor source 3) A patient undergone HCT at age 20 or more

Exclusion criteria

Exclusion criteria: 1) A patient who was confirmed HBs antigen positive before HCT 2) A patient treat by nucleotide analogue before the diagnosis of HBV reactivation 3) A patient who refuses entry to the study

Design outcomes

Primary

Measure	Time frame
re-reactivation of HBV after cessation of nucleotide analogue	—

Countries

Japan

Contacts

Public ContactMasahiro Onozawa

Hokkaido University Hospital Department of Hematology

onozawa@med.hokudai.ac.jp011-716-1161

Outcome results